Remember the "soul bargain"? The fourth batch of drug collection will start.

Release time:


Health is a matter of vital importance to the people. In order to gradually solve the problem of expensive medical treatment, in recent years, the state has promoted major reforms in the centralized procurement and use of drugs. The executive meeting of the State Council held on January 15 deployed to further promote the reform of centralized drug procurement, and reduce the burden of medical treatment for the masses with normalized and institutionalized measures.

The centralized drug procurement organized by the state is in accordance with the general idea of "national organization, alliance procurement, and platform operation", with public hospitals in the alliance area as the main body of centralized procurement, adopting the methods of volume procurement, volume-price linkage, and volume-for-price exchange, and drug manufacturers Negotiate to reduce drug prices and reduce the burden of patients' medical expenses.

The strength of the bargaining and price reduction of some drugs and the surprise of the bargaining experts' negotiation methods have been called "soul bargaining" by the media and netizens, which can be described as "famous scenes" constantly:

"4.4 yuan, 4 is too much, the Chinese think bad, another 4 cents down, 4.36, OK?" In November 2019, this price-cutting video hit the Internet, in the face of the old hot National Health Insurance Bureau negotiators, pharmaceutical companies representatives repeatedly out of the negotiation venue to call to discuss the offer, drug prices from 5.62 yuan to 4.36 yuan, and finally to the world's lowest price to deal;

"It's lower than that of 10 yuan, '9 yuan can be divided by 9 cents.' This is very nice." On November 25, 2020, the first batch of drugs in Shandong Province was opened for centralized procurement, and a video of bargaining experts and pharmaceutical company representatives for a price cut for a blood pressure drug was "on fire" again. In fact, the bid opening involved 160 products from 73 enterprises, with an average price reduction of 67.3 per cent and a maximum reduction of 98.58 per cent;


By the end of 2020, China has carried out three batches of centralized procurement, covering an average price reduction of 54%, saving more than 53 billion yuan per year, benefiting hundreds of millions of patients.

The executive meeting of the State Council pointed out that the fourth batch of collection will be carried out in the near future, and the scope of collection of high-value medical consumables will be expanded. The meeting called for the deployment of medical reform, adhere to the three medical linkage, and promote the normalization and institutionalization of drug collection:

First, in accordance with the principle of basic and clinical protection, the focus will be on the basic medical insurance drug list of drugs with large dosage and high purchase amount into the scope of procurement, and gradually cover all kinds of drugs and consumables that are clinically necessary and reliable in quality on the domestic market. Public medical institutions should participate in the collection. Research on special arrangements for the procurement of "orphan drugs" for the treatment of rare diseases;

Second, eligible generic drugs, original research drugs and reference preparations are all in the generic name to participate in the collection, through quality and price fair competition to produce the selected enterprises and drugs, consumables. Medical institutions should ensure that the use of selected drugs is prioritized and that purchases are made as much as possible as needed. The selected enterprises should ensure that the price reduction does not reduce the quality, does not reduce the efficacy, to ensure supply. Strengthen the supervision of the whole chain of production, circulation and use of selected drugs and consumables;

Third, centralized procurement should reduce the burden on patients while taking into account the reasonable profits of enterprises, promote the concentration of the pharmaceutical and consumables industry in the competition, promote product innovation and upgrading, and give medical institutions a surplus retention incentive for the saved medical insurance costs according to regulations, so as to make this reform benefit both patients, enterprises and medical institutions.